This approach was demonstrated in the treatment of malignant pleural mesothelioma with TargomiR, which consisted of miR-16 mimics packaged in bacteria-derived nanoparticles labelled with an EGFR-antibody16. The gene discussed is EGFR; the disease is malignant pleural mesothelioma.